1. Company Overview
AGS Health Limited is a technology-enabled healthcare Revenue Cycle Management (RCM) company serving healthcare providers primarily in the United States.
The company helps hospitals, health systems and physician groups manage various stages of the healthcare revenue cycle — from patient access and eligibility to medical coding, claims processing, denial management, accounts receivable and collections.
AGS combines AI, automation, analytics, healthcare expertise and global delivery capabilities to help healthcare providers improve revenue realization and reduce administrative costs. The company was incorporated in 2010 and has evolved from a healthcare outsourcing business into a technology-enabled RCM platform.
2. Company Details
| Particular | Details |
|---|---|
| Company | AGS Health Limited |
| CIN | U72200TN2010PLC078062 |
| Incorporated | 12 November 2010 |
| Status | Unlisted Public Company |
| Registered Office | Chennai, Tamil Nadu |
| Global Headquarters | Washington, D.C., USA |
| Industry | Healthcare Technology / RCM |
| Core Market | United States |
| Current Ownership | Blackstone |
| FY26 Employees | ~15,895 |
| FY26 Customers | 149 |
| Hospital / Health-System Customers | 82 |
| Global Delivery Sites | 10 |
AGS Health’s official corporate information states that the company had more than 15,000 RCM professionals globally in 2025, with operations across India, the Philippines, Mexico and the U.S.
3. What Does AGS Health Do?
AGS Health operates across a large portion of the healthcare revenue cycle.
Front-End RCM
- Patient access
- Eligibility and insurance verification
- Financial clearance
- Prior authorization
- Patient financial engagement
- Provider enrollment and credentialing
Mid-Cycle RCM
- Medical coding
- Clinical documentation improvement
- Revenue integrity
- Coding audit
- Compliance solutions
- Care management
Back-End RCM
- Claims processing
- Claims posting
- Denial management
- Underpayment recovery
- Accounts receivable
- Collections
- Patient billing
The company states that its technology and services span approximately 80% of the healthcare RCM value chain.
4. Technology & AI
Technology has become increasingly important to AGS Health’s business model.
Its technology capabilities include:
- Computer-assisted coding
- Clinical documentation improvement
- Coding audit
- Revenue-cycle automation
- Intelligent authorization
- Autonomous coding
- Analytics
- Workflow automation
- AI-enabled revenue-cycle solutions
AGS launched its broader AI platform in 2022 and has subsequently expanded its technology capabilities through acquisitions and product development.
The company’s focus is increasingly shifting from traditional manpower-based healthcare outsourcing toward technology-enabled RCM and AI-assisted workflows.
5. Customer Base
AGS Health primarily serves U.S. healthcare organizations, including:
- Large hospital systems
- Healthcare networks
- Physician groups
- Specialty healthcare providers
- Integrated delivery networks
As of FY2026, the company reported:
| Customer Metric | FY2026 |
|---|---|
| Total Customers | 149 |
| Hospital / Health-System Customers | 82 |
| Customers generating >$1 million revenue | 30 |
| Global Employees | 15,895 |
| Global Delivery Sites | 10 |
AGS stated that it served 11 of the top 20 U.S. hospitals as of March 2026.
6. Customer Concentration
Customer concentration remains an important factor for investors to monitor.
According to the company’s latest filing:
- Top 5 customers contributed approximately 51.82% of FY26 reported revenue
- Top 10 customers contributed approximately 68.56%
- Average tenure of the top five customers was approximately 8.08 years
The long customer relationships can support visibility, but the concentration also means that the loss or reduction of business from a major customer could materially affect revenue.
7. FY2026 Financial Performance
The latest UDRHP provides consolidated financial information through FY2026.
| ₹ Crore | FY2024 | FY2025 | FY2026 |
|---|---|---|---|
| Revenue from Operations | 988.97 | 1,194.89 | 2,041.42 |
| EBITDA | 213.02 | 318.37 | 780.17 |
| EBITDA Margin | 21.54% | 26.64% | 38.22% |
| PAT | 115.64 | 142.93 | 206.95 |
| PAT Margin | 11.69% | 11.96% | 10.14% |
| Net Worth | 511.62 | 653.61 | 4,551.61 |
| Borrowings | Nil | Nil | 4,238.81 |
FY2026 revenue increased to approximately ₹2,041 crore, while EBITDA reached approximately ₹780 crore and reported PAT was approximately ₹207 crore.
Important Financial Consideration
FY2026 reflects the company’s post-acquisition/consolidated structure, meaning direct comparisons with earlier standalone years should be interpreted carefully.
The UDRHP also provides pro-forma information:
| ₹ Crore | FY2024 Pro Forma | FY2025 Pro Forma | FY2026 |
|---|---|---|---|
| Revenue | 1,378.21 | 1,779.94 | 2,164.36 |
| EBITDA | 408.79 | 628.98 | 780.15 |
| EBITDA Margin | 29.66% | 35.34% | 36.05% |
| PAT | -345.52 | -275.99 | -141.04 |
The pro-forma numbers incorporate the relevant acquisition structure and therefore provide a different view of the historical financial profile.
8. EBITDA Margin Expansion
One of the most notable reported changes is the expansion in EBITDA margin:
FY24: 21.54%
FY25: 26.64%
FY26: 38.22%
The improvement reflects the company’s technology-enabled operating model, automation, specialized healthcare capabilities and global delivery infrastructure.
However, investors should distinguish between EBITDA growth and reported PAT, particularly because FY2026 includes acquisition-related and other accounting effects.
9. U.S. Healthcare RCM Opportunity
AGS Health operates in the U.S. healthcare market, where the administrative complexity of healthcare billing creates demand for specialized RCM providers.
The industry research cited in the company’s filing estimates:
- U.S. healthcare expenditure in 2025: approximately $5.6 trillion
- U.S. RCM spend in 2025: approximately $234.5 billion
- Estimated RCM market in 2030: approximately $329.8 billion
- Estimated 2025–2030 CAGR: approximately 7.1%
Growth drivers include increasing claims complexity, reimbursement pressures, healthcare administrative costs, denial management requirements and adoption of technology-enabled outsourcing.
10. Blackstone Ownership
A major corporate development was the acquisition of AGS Health by Blackstone in August 2025.
AGS had previously been owned by Baring Private Equity Asia/EQT. Public transaction records report the Blackstone acquisition at approximately $1.4 billion.
Blackstone ownership has been followed by preparations for an Indian public-market listing.
11. Strategic Acquisitions & Expansion
EZDI Acquisition
AGS acquired EZDI in 2021, adding AI-based clinical documentation and medical-coding technology capabilities.
Availity India Business
In 2023, AGS acquired Availity’s India-based patient-access outsourcing business along with its Intelligent Authorization technology.
Philippines Expansion
The company expanded into the Philippines to strengthen business continuity and enhance capabilities in patient outreach, clinical services and accounts receivable.
Mexico Expansion
In 2025, AGS expanded its global delivery footprint with a near-shore delivery centre in Guadalajara, Mexico.
12. IPO Plans
AGS Health has moved significantly closer to a public listing.
SEBI’s processing-status documents identify AGS Health’s filing as an IPO comprising Fresh Issue + Offer for Sale.
The latest UDRHP proposes:
| IPO Component | Proposed Amount |
|---|---|
| Fresh Issue | Up to ₹1,800 Cr |
| Offer for Sale | Up to ₹3,000 Cr |
| Total Proposed IPO | Up to ₹4,800 Cr |
| Possible Pre-IPO Placement | Up to ₹360 Cr |
| Proposed Listing | NSE & BSE |
The OFS is proposed to be sold by BCP Asia II Topco VIII Pte. Ltd., the promoter entity.
13. Use of IPO Proceeds
Approximately ₹1,600 crore from the fresh issue is proposed to be used toward repayment or prepayment of certain borrowings of AGS Health’s indirect subsidiaries.
The remaining proceeds are proposed to be used for general corporate purposes and issue-related expenses.
Therefore, the fresh issue has a meaningful balance-sheet deleveraging component.
14. Proposed Shareholding
Before the proposed IPO, BCP Asia II Topco VIII Pte. Ltd. holds approximately 98.54% of AGS Health according to the latest filing information.
The proposed OFS provides the promoter an opportunity to monetize part of its holding while the fresh issue raises capital for the company/group.
15. IPO Valuation
Earlier media reports indicated that Blackstone was considering an AGS Health valuation of up to approximately $3 billion during the IPO planning process.
However, this should not be treated as the final IPO valuation.
The final IPO price band and offer price have not yet been announced. Investors should therefore evaluate any pre-IPO/unlisted transaction against the eventual IPO valuation once the price band is officially disclosed.
The UDRHP also discloses a promoter weighted-average acquisition cost of approximately ₹204.04 per equity share. This is historical acquisition information and should not be interpreted as a current market value or price target.
16. Key Growth Drivers
1. Expansion of U.S. healthcare outsourcing
Increasing administrative complexity can support demand for specialized RCM providers.
2. AI & Automation
AI-assisted coding, authorization, claims processing and denial management can potentially improve productivity.
3. Cross-Selling
AGS can offer multiple services to existing customers across different stages of the revenue cycle.
4. Large Enterprise Customers
Relationships with large U.S. healthcare organizations can provide recurring business opportunities.
5. Global Delivery Model
India, Philippines and Mexico provide a diversified delivery footprint.
6. Deleveraging
The proposed ₹1,600 crore allocation toward debt repayment could reduce financial leverage at the relevant subsidiaries if the IPO is completed as proposed.
17. Key Risks
Customer Concentration
The top five customers represented more than half of FY26 reported revenue, creating exposure to customer concentration risk.
High Borrowings
FY26 consolidated borrowings were approximately ₹4,239 crore. Debt reduction is therefore an important factor to monitor.
U.S. Market Dependence
The business is predominantly exposed to U.S. healthcare providers, making it sensitive to changes in healthcare reimbursement, regulation and provider economics.
Technology Risk
The RCM industry is increasingly adopting AI and automation. AGS will need to continue investing in technology to remain competitive.
Employee Attrition
Healthcare RCM remains a people-intensive industry, and retaining trained healthcare professionals is important for maintaining service quality and margins.
Acquisition / Integration Risk
The company has grown through acquisitions and operates across multiple countries. Integrating technology, processes and teams across geographies remains an execution consideration.
Valuation Risk
The final IPO price has not yet been announced. Any unlisted investment should therefore be evaluated against the eventual IPO valuation rather than relying only on reported historical transaction values.
18. AGS Health vs Traditional Healthcare BPO
AGS Health’s evolution can broadly be viewed as:
Traditional Healthcare BPO → Technology-enabled RCM → AI-driven Healthcare Revenue Platform
The company is increasingly combining:
- AI
- SaaS
- Automation
- Analytics
- Healthcare expertise
- Global delivery
- Revenue-cycle intelligence
The company reported that approximately 14.50% of FY26 revenue came from customers using both SaaS solutions and technology-enabled services.
19. IPO / Unlisted Status – September 2026
As of the latest available information:
| Parameter | Status |
|---|---|
| Company | AGS Health Limited |
| Current Status | Unlisted |
| IPO Filing | Yes |
| Latest Document | UDRHP |
| Proposed IPO Size | ₹4,800 Cr |
| Fresh Issue | ₹1,800 Cr |
| OFS | ₹3,000 Cr |
| Proposed Exchanges | NSE & BSE |
| Price Band | Not announced |
| IPO Opening Date | Not announced |
| Listing Date | Not announced |
| Promoter | BCP Asia II Topco VIII Pte. Ltd. |
| Controlling Owner | Blackstone |
The proposed IPO remains subject to the applicable regulatory and market processes, and the final price band and issue dates are yet to be announced.
20. Unlisted Investment Perspective
AGS Health represents a relatively differentiated healthcare opportunity because it is not a hospital, diagnostic company or pharmaceutical manufacturer.
It operates in the healthcare services and technology ecosystem, specifically in U.S. healthcare revenue-cycle management.
Key factors investors may monitor include:
- FY26 revenue of approximately ₹2,041 Cr
- FY26 EBITDA of approximately ₹780 Cr
- FY26 PAT of approximately ₹207 Cr
- Strong reported EBITDA-margin expansion
- 149 customers
- 82 hospital/health-system customers
- 15,895 employees
- Exposure to 11 of the top 20 U.S. hospitals
- Blackstone ownership
- Proposed ₹4,800 Cr IPO
- ₹1,800 Cr fresh capital
- ₹3,000 Cr OFS
- Proposed ₹1,600 Cr debt repayment
- Customer concentration
- Final IPO valuation
The most important consideration for an unlisted investor is likely to be the price paid before listing compared with the eventual IPO valuation and the company’s post-IPO financial profile.
21. Company Snapshot
| Parameter | AGS Health Limited |
|---|---|
| Sector | Healthcare Technology / RCM |
| Geography | Primarily U.S. |
| FY26 Revenue | ₹2,041.42 Cr |
| FY26 EBITDA | ₹780.17 Cr |
| FY26 PAT | ₹206.95 Cr |
| FY26 EBITDA Margin | 38.22% |
| FY26 Net Worth | ₹4,551.61 Cr |
| FY26 Borrowings | ₹4,238.81 Cr |
| Customers | 149 |
| Hospital/Health-System Customers | 82 |
| Employees | 15,895 |
| Global Delivery Sites | 10 |
| Promoter | BCP Asia II Topco VIII Pte. Ltd. |
| Owner | Blackstone |
| Proposed IPO | ₹4,800 Cr |
| Fresh Issue | ₹1,800 Cr |
| OFS | ₹3,000 Cr |
| Proposed Listing | NSE & BSE |
| Current Status | Unlisted |
22. Important Links
Official AGS Health Website:
AGS Health – Official Website
AGS Health – Company & History:
AGS Health Company Information
SEBI – Draft Offer Document Processing Status:
SEBI Draft Offer Documents
AGS Health IPO / Offer Document Information:
Jefferies – AGS Health Offer Documents
AGS Health – UnlistedCart:
AGS Health Limited on UnlistedCart
23. Disclaimer
This report is prepared for informational and educational purposes only and should not be construed as investment advice, an offer to buy or sell securities, or a guarantee of future returns.
AGS Health Limited is currently unlisted and its proposed IPO, issue size, price band, dates and other terms may change before the final offer document.
Financial figures and business information have been compiled from publicly available company disclosures, regulatory filings and secondary sources. Investors should independently review the latest SEBI filings, financial statements, valuation and applicable transaction documents before making any investment decision.
Unlisted and pre-IPO investments can involve liquidity risk, valuation risk, regulatory risk and limited price discovery. Past financial performance does not guarantee future performance.
For more such unlisted stocks visit:
UnlistedCart – Unlisted Shares
